查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2096453

骨質密度檢測設備：市場洞察、競爭格局及市場預測 - 2034 年

Bone Densitometers - Market Insights, Competitive Landscape, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

骨質密度檢測設備市場概述

概述：

  • 2025年全球骨質密度檢測設備市值為7.9億美元，預計2034年將達到12.4億美元。
  • 預計在2026年至2034年的預測期內，該市場將以 5.15%的CAGR成長，其促進因素包括骨質疏鬆症和骨質減少症的患病率上升、全球人口老齡化、脆性骨折負擔加重、向非放射性檢測的轉變以及骨質指數和人工智慧（AI）融入骨骼密度測量工作流程（AI）。
  • 依技術分類，2025年軸向（中心）骨骼密度領域將佔據71%的市場佔有率，成為骨質密度檢測設備市場的主要驅動力。在該領域內，中心雙能量X光檢測法（DXA）仍然是標準的檢查方法。
  • 依應用領域分類，到2025年，用於診斷骨質疏鬆症和骨質減少症的細分市場佔骨質密度檢測設備市場的74%，推動市場向前發展。
  • 就便攜性而言，到2025年，固定式和獨立式系統細分市場將引領骨質密度檢測設備市場，佔據 63%的市場佔有率。
  • 依最終用戶分類，醫院領域預計將推動骨質密度檢測設備市場的發展，到2025年將佔市場佔有率的52%。
  • 截至2025年，北美在骨質密度檢測設備市場中佔據最大佔有率，為 44%，但預計到2034年，亞太地區將實現最快成長。

骨質密度檢測設備是一種用於測量骨骼密度和評估骨折風險的診斷設備，主要用於檢測和後續觀察骨質疏鬆症和骨質缺乏症。要善加理解這一類別，可以參考製造商用於組織產品系列的臨床路徑。標準檢測方法為中心式雙能量X光檢測法（DXA）。此方法使用兩種不同能量的X光照射腰椎和股骨近端，以計算骨骼密度並產生T值和Z值。先進的系統也會產生「小樑骨評分」作為評估骨質的指標。中心式系統擴大將椎體骨折評估、腹主動脈鈣化篩檢以及脂肪量和瘦體重的全身成分分析整合到同一平台上。利用周邊雙能量X光檢測法、周邊定量電腦斷層掃描和定量超音波等技術的周邊設備，可將測量範圍擴展至前臂和跟骨，並廣泛應用於基層醫療、篩檢和即時檢測等需要小型或可攜式設備的場所。中心定量CT則使用配備專用軟體的標準CT掃描儀測量體積骨骼密度。該領域近期最重要的進展是射頻回波多波長光譜技術。這是超音波方式，無需使用電離輻射即可評估脊椎和髖部的骨骼密度和骨質，即使對於有輻射暴露風險的受試者，也可以進行重複掃描。目前市場的特點是：從單純評估骨量轉向骨量和骨品質的聯合評估；無輻射軸向成像方式的出現；骨折風險演算法和人工智慧（AI）被整合到報告中；以及骨骼密度測量從三級醫療機構擴展到基層醫療和健康管理機構。

骨質密度檢測設備市場的主要市場促進因素

  • 骨質疏鬆症和骨質缺乏症的盛行率上升。根據國際骨質疏鬆症基金會的報告，50歲以上的女性中，每三人就有一人；50歲以上的男性中，每五人就有一人會在餘生中經歷與骨質疏鬆症相關的骨折。
  • 脆性骨折是日益嚴重的健康負擔。根據國際骨質疏鬆症基金會統計，每年55歲以上族群發生脆性骨折的病例高達3,700萬例，相當於每分鐘70例。
  • 世界人口迅速老化。根據聯合國的報告，2020年65歲及以上人口數量為7.27億，預計2050年將超過15億人。
  • 股骨頸骨折的負擔日益加重，預計2018年至2050年間病例數將激增。此外，亞洲大部分股骨頸骨折預計將發生在中國。
  • 產品設計的技術進步包括將骨小梁評分、骨折風險演算法和人工智慧整合到骨骼密度測量報告中。
  • 一種利用高頻回波多波長光譜技術的無輻射軸向評估方法已經問世。該方法已通過檢驗，符合現行醫療程序術語（CPT）的保險償付條件，該術語將於2024年1月生效。目前，美國國家航空暨太空總署（NASA）使用該方法監測骨骼健康。
  • 緊湊便攜的超音波系統將骨骼密度檢測從三級醫療放射科擴展到基層醫療、健康保健和即時護理場所。

推動骨質密度檢測設備市場成長的因素

市場促進因素

骨質疏鬆症和骨質減少症的盛行率不斷上升

骨質密度檢測設備市場的主要驅動力是骨質疏鬆症和骨質缺乏症盛行率的上升，催生了對診斷和監測的需求，而這正是整個骨密度儀市場的基礎。骨質疏鬆症進展緩慢，骨骼逐漸脆弱，直到骨折發生。根據國際骨質疏鬆症基金會統計，50歲以上的女性中，三分之一、男性中，五分之一的人一生中會經歷與骨質疏鬆症相關的骨折。這一風險高於女性罹患乳癌的風險，也高於男性罹患攝護腺癌的風險。世界衛生組織（WHO）將骨質疏鬆症定義為骨骼密度T值低於-2.5，由於此閾值只能透過骨骼密度確定，因此所有高風險族群都應接受檢測，接受治療的患者則需要在接下來的幾年中進行一系列後續觀察檢查。停經後婦女是篩檢的主要目標族群，因為隨著雌激素值的下降，她們的骨骼密度會顯著降低。同時，糖皮質激素治療、內分泌疾病、類風濕性關節炎和惡性腫瘤引起的次發性骨質疏鬆症進一步擴大了符合篩檢的人。隨著臨床指南擴大建議對65歲及以上的女性以及存在風險因素的年輕患者進行骨骼密度檢測，已開發國家和新興市場符合篩檢條件的人群都在持續成長，推動了對中心和外周骨骼密度測量系統的需求。

脆性骨折負擔加重

脆性骨折負擔日益加重，是促使無症狀骨質流失轉化為可見的臨床和經濟影響的強大驅動力，因此需要醫療保健系統採取預防措施。根據國際骨質疏鬆症基金會統計，每年55歲以上族群中發生多達3,700萬例脆性骨折，相當於每分鐘70例。此外，世界衛生組織（WHO）的紀錄顯示，2019年全球整體新增骨折1.78億例，通報病例達4.55億例。脆性骨折後果嚴重；股骨頸骨折常使患者難以獨立生活，相當一部分倖存者在隨後一年內需要幫助或入住養老機構。因此，預防和早期發現繼發性骨折已成為一項政策重點，體現在骨折聯絡服務和篩檢計畫中，這些計畫目的是指導高風險患者進行骨骼密度測量。由於先前骨折會顯著增加再次骨折的風險，因此每例脆性骨折都會增加後續藥物治療期間定期監測以及診斷性檢查的需求，以識別潛在的骨骼脆弱性。此外，與骨折相關的巨大且不斷成長的醫療保健成本進一步凸顯了骨骼密度檢測作為預防基礎的重要性。

市場限制因素

骨質密度檢測設備市場面臨許多限制和挑戰，主要集中在保險償付、公眾認知和可及性方面。長期以來，許多醫療體系對骨骼密度的保險償付額度有限。償付額度不足或持續下降阻礙了醫療機構對設備的投資，進而可能限制了監測檢測的頻率。這導致新系統的引進和老舊系統的更換都受到延誤。患者（在某些情況下甚至是基層醫療提供者）普遍缺乏相關認知，這意味著絕大多數骨質疏鬆症患者直到發生骨折才被確診。儘管技術已經成熟，但仍有很大一部分目標族群錯失了接受檢測的機會。中心雙能X光檢測法（DXA）系統的高成本、對屏蔽室和專業技術人員的需求，以及為品管而定期進行體模校準的要求，進一步限制了骨密度儀的普及。在開發中國家和農村地區，這一趨勢尤其突出，因為這些地區很大一部分人口根本無法獲得骨質密度檢測設備。監管趨勢也加劇了這一負擔。歐盟醫療設備法規對臨床證據和文件提出了廣泛的要求，增加了維持產品供應的合規成本，並使具備監管能力的大規模製造商佔據優勢。主要供應商為多種產品重新認證的努力也反映了這一趨勢。周邊設備和超音波領域的競爭日益激烈，眾多區域製造商提供低成本系統，導致價格競爭異常激烈。同時，不同製造商系統間交叉校準的差異，使得患者更換設備時的時間序列監測變得複雜。貿易政策和供應鏈壓力對電子元件、檢測器和X光組件也進一步限制了製造成本和前置作業時間。

區域說明

北美洲

北美在市場規模、部署數量和保險償付方面佔據主導領先，到2025年佔據44%的市場佔有率。美國擁有兩家主要的中央雙能量X光吸收測量法（DEXA）檢測法製造商，且射頻檢測法（RPEM）的現行程序術語（CPT）代碼已於2024年1月生效。美國疾病管制與預防中心（CDC）報告指出，50歲及以上成年人（尤其是女性）的骨質疏鬆症盛行率極高。完善的保險償付體系、針對65歲及以上女性的指南性篩檢以及醫院和影像中心的密集部署，都為該技術的廣泛應用提供了支持。短期趨勢受骨骼品質指標和身體組成分析、無輻射評估以及檢測範圍擴展到初級保健和健康管理領域等因素的影響。

歐洲

歐洲是一個成熟大規模的市場，其促進因素包括大規模的老齡人口、高發生率的脆性骨折以及對透過骨折聯絡服務進行二級骨折預防的高度重視。脆性骨折在歐洲的藥物經濟學成本巨大且持續成長，這進一步強化了篩檢和骨骼密度測量的政策合理性。歐盟醫療設備法規對證據和文件提出了廣泛的要求，這重塑了產品的供應格局，並使具備合規能力的製造商獲得了優勢。這一點也體現在眾多產品的重新認證工作中。射頻回波光譜技術起源於義大利，目前在歐洲的臨床應用日益廣泛，但其使用受到各國篩檢計畫和指引建議的影響。

亞太地區

亞太地區是成長最快的地區，這主要得益於龐大且迅速老化的人口、骨質疏鬆症和骨折發病率的上升以及醫療保健投資的不斷成長。預計到2050年，全球超過一半的骨質疏鬆性骨折將發生在亞洲，其中中國髖部骨折的發生率預計將大幅增加。政府措施、不斷擴大的保險覆蓋範圍以及韓國、中國和日本成熟的、具有成本效益的製造商群體加速該技術的普及，檢測範圍也正從三級醫療機構擴展到該地區的基層醫療機構。韓國和中國的製造商為國內和出口市場提供價格合理的中心和末梢用系統，而日本的製造商則提供定量超音波技術。

世界其他地區

世界其他地區，例如中東、非洲和南美洲，骨質疏鬆症檢測的普及程度仍參差不齊。波灣合作理事會（GCC）成員國和龐大的南美市場（尤其是巴西）正經歷著成長，這得益於對影像技術的投資以及最先進的骨骼密度測量技術的日益普及。同時，在非洲許多地區，由於缺乏必要的基礎設施、訓練有素的人員以及骨骼密度檢測所需的資金，相當一部分骨質疏鬆症患者仍未得到診斷。高昂的檢測系統和費用限制了開發中國家的骨質疏鬆症檢測普及，在許多情況下，這些費用不在醫療保險範圍內。該地區的成長將受到以下因素的推動：對診斷能力的投資、政府的衛生政策、宣傳活動，以及來自亞洲和歐洲製造商的低成本攜帶式超音波檢測系統。

骨質密度檢測設備市場的最新發展趨勢

2025年11月，Echolight SpA在芝加哥舉行的北美放射學會（RSNA）2025年年會上展示了一種無輻射射頻檢測法圖多波長骨骼密度技術，並發表了兩項新的檢驗研究，其中包括將此技術應用於評估妊娠期和全髖置換術術後的骨骼變化。策略意義：該技術在輻射暴露風險較高的人群中獲得了經同行評審的最新檢驗結果，在業內規模最大的診斷成像會議上展示無輻射軸向評估技術，將加速該技術的臨床應用，使其突破固定X光設備的局限性，實現更全面的骨骼評估。

2026年2月，MRIguidance進一步推進了其無輻射骨骼影像解決方案BoneMRI的研發，鞏固了其市場領先地位，加速了基於磁振造影的定量骨骼密度的普及應用。戰略意義：基於磁振造影的骨骼密度的出現，對X光雙能檢測法提出了又一項無輻射挑戰，表明該領域的技術前沿正朝著一種既能避免電離輻射又能提供結構資訊的成像方式轉變。

常見問題：

問題1：骨質密度檢測設備市場的預期成長率是多少？

全球骨質密度檢測設備市場預計在2026年至2034年的預測期內將以 5.15%的CAGR成長。

Q2.目前骨質密度檢測設備市場的規模和預期規模是多少？

2025年全球骨質密度檢測設備市值為7.9億美元，預計2034年將達到12.4億美元。

Q3.哪些地區推動骨質密度檢測設備市場的發展？

到2025年，北美將以44%的市場佔有率引領骨密度儀市場，這主要得益於骨質疏鬆症的高發病率、先進的醫療基礎設施、完善的保險償付體系和基於指南的篩檢，以及兩家領先的中心雙能X骨質密度檢測設備檢測法儀（DXA）製造商的存在。主導到2034年，亞太地區將實現最高的CAGR，這主要受龐大且快速老化的人口、日益嚴重的骨折負擔以及成熟的具成本效益製造商群體所驅動。

目錄

第1章 引言

  • 調查範圍
  • 市場區隔
  • 市場概覽

第2章 骨質密度檢測設備：執行摘要

  • 主要亮點和市場概覽

第3章 影響骨質密度檢測設備市場的關鍵因素

  • 市場促進因素
    • 骨質疏鬆症和骨質減少症盛行率增加
    • 脆性骨折導致的應力增加
    • 世界人口老化
    • 技術進步與骨質評估
    • 不使用輻射的軸向成像技術的出現。
  • 市場限制因素
    • 保險償付限制和認知度低
    • 開發中國家的高成本和有限的取得途徑
    • 監理負擔和競爭壓力
  • 市場機會
    • 將骨骼評估擴展到基層醫療
    • 人工智慧與骨質指標的整合

第4章 影響分析：人工智慧、地緣政治、貿易和經濟趨勢

第5章 監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章 波特五力分析

  • 供應商的議價能力
  • 消費者議價能力
  • 新進入者的威脅
  • 替代品的威脅
  • 競爭公司之間的競爭

第7章 骨質密度檢測設備市場評估

  • 依技術
    • 軸向（中心）骨骼密度測量
    • 周邊骨骨密度測量
    • 射頻回波多波長光譜（REMS）
  • 依用途
    • 骨質疏鬆症和骨質減少症的診斷
    • 骨折風險評估
    • 身體組成分析
    • 其他
  • 依便攜性
    • 固定式和獨立式系統
    • 可攜式和桌上型系統
  • 依最終用戶
    • 醫院
    • 診斷影像中心
    • 門診部和專科診所
  • 依地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第8章 骨質密度檢測設備市場的競爭格局

  • 競爭分析
  • 企業市場占有率分析（高級版）

第9章 骨質密度檢測設備市場的新創企業資金籌措與投資趨勢

第10章 公司簡介與產品簡介

  • GE HealthCare Technologies Inc.
    • 公司簡介
    • 公司簡介
    • 財務概覽
    • 產品列表
    • 策略舉措/熵
  • Hologic, Inc.
  • Echolight SpA
  • OsteoSys Co., Ltd.
  • BeamMed Ltd.
  • Diagnostic Medical Systems（DMS）Group
  • Swissray International, Inc.
  • Trivitron Healthcare Pvt. Ltd.
  • Furuno Electric Co., Ltd.
  • Xingaoyi Medical Equipment Co., Ltd.

第11章 KOL的觀點

第12章 專案方法

第13章 關於 DelveInsight

第14章 免責聲明與聯絡方式

Product Code: DIMDCL0081

Bone Densitometers Market Summary

Overview:

  • The global bone densitometers market was valued at USD 790 million in 2025 and is projected to reach USD 1.24 billion by 2034.
  • The market is expected to expand at a CAGR of 5.15% during the forecast period 2026-2034, supported by the rising prevalence of osteoporosis and osteopenia, the ageing of the global population, the growing burden of fragility fractures, the shift toward radiation-free assessment, and the integration of bone quality metrics and artificial intelligence into densitometry workflows.
  • By technology, the axial (central) bone densitometry segment dominated the bone densitometers market with a 71% share in 2025, within which central dual-energy X-ray absorptiometry remains the reference modality.
  • By application, the osteoporosis and osteopenia diagnosis segment dominated the bone densitometers market with a 74% share in 2025.
  • By portability, the stationary and standalone systems segment dominated the bone densitometers market with a 63% share in 2025.
  • By end-user, the hospitals segment dominated the bone densitometers market with a 52% share in 2025.
  • North America accounted for the largest share of the bone densitometers market at 44% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.

A bone densitometer is a diagnostic device that measures bone mineral density and estimates fracture risk, most commonly to detect and monitor osteoporosis and osteopenia. The category is best understood through the clinical pathway that manufacturers themselves use to organize their portfolios. The reference modality is central dual-energy X-ray absorptiometry, in which two X-ray energies are passed through the lumbar spine and proximal femur to compute bone mineral density, generate T-scores and Z-scores, and, in advanced systems, derive the Trabecular Bone Score as a measure of bone quality. Central systems increasingly integrate vertebral fracture assessment, abdominal aortic calcification screening, and whole-body composition analysis of fat and lean mass on the same platform. Peripheral devices extend measurement to the forearm and calcaneus through peripheral dual-energy X-ray absorptiometry, peripheral quantitative computed tomography, and quantitative ultrasound, serving primary care, screening, and point-of-care settings where a compact or portable footprint is required. Central quantitative computed tomography provides volumetric bone density using standard computed tomography scanners with dedicated software. The most significant recent addition to the category is radiofrequency echographic multispectrometry, an axial ultrasound modality that assesses bone density and quality at the spine and hip without ionizing radiation, enabling repeat scanning in populations for whom radiation exposure is a concern. The contemporary market is defined by the transition from bone quantity alone toward combined bone quantity and quality assessment, the emergence of radiation-free axial modalities, the embedding of fracture-risk algorithms and artificial intelligence into reporting, and the extension of densitometry from tertiary radiology into primary care and wellness settings.

Bone Densitometers Market Key Growth Drivers

  • Rising prevalence of osteoporosis and osteopenia, with the International Osteoporosis Foundation reporting that one in three women and one in five men over the age of 50 will experience an osteoporosis-related fracture over their remaining lifetimes.
  • A large and growing fragility fracture burden, with the International Osteoporosis Foundation reporting up to 37 million fragility fractures each year in individuals over the age of 55, equivalent to 70 fractures every minute.
  • Rapid ageing of the global population, with the United Nations reporting 727 million people aged 65 or over in 2020, a figure projected to exceed 1.5 billion by 2050.
  • A rising hip fracture burden, with the number of hip fractures projected to rise sharply between 2018 and 2050, and the majority of Asian hip fractures expected to occur in China.
  • Technological advancement in product design, including the integration of the Trabecular Bone Score, fracture-risk algorithms, and artificial intelligence into densitometry reporting.
  • Emergence of radiation-free axial assessment through radiofrequency echographic multispectrometry, validated by Current Procedural Terminology reimbursement effective from January 2024 and adoption by NASA for bone health monitoring.
  • Extension of bone density testing from tertiary radiology into primary care, wellness, and point-of-care settings through compact, portable, and ultrasound-based systems.

Key Companies in Bone Densitometers Market

The competitive landscape is led by the following active players:

  • GE HealthCare Technologies Inc.
  • Hologic, Inc.
  • Echolight S.p.A.
  • OsteoSys Co., Ltd.
  • BeamMed Ltd.
  • Diagnostic Medical Systems (DMS) Group
  • Swissray International, Inc.
  • Trivitron Healthcare Pvt. Ltd.
  • Furuno Electric Co., Ltd.
  • Xingaoyi Medical Equipment Co., Ltd.

Factors Contributing to the Growth of the Bone Densitometers Market

Market Drivers

Rising Prevalence of Osteoporosis and Osteopenia

The foundational driver of the bone densitometers market is the rising prevalence of osteoporosis and osteopenia, which generates the diagnostic and monitoring volume on which the entire category depends. Osteoporosis progresses silently, weakening bone until a fracture occurs, and the International Osteoporosis Foundation reports that one in three women and one in five men over the age of 50 will experience an osteoporosis-related fracture over their remaining lifetimes, a risk that in women exceeds that of breast cancer and in men exceeds that of prostate cancer. Because the World Health Organization defines osteoporosis by a bone mineral density T-score at or below minus 2.5, and because that threshold can be established only by densitometry, each patient at risk represents a probable scan and, for those on treatment, a series of monitoring scans over subsequent years. Postmenopausal women constitute the primary screening population, driven by the marked decline in bone mineral density that accompanies estrogen loss, while secondary osteoporosis arising from glucocorticoid therapy, endocrine disorders, rheumatoid arthritis, and malignancy widens the eligible pool further. As clinical guidelines increasingly recommend bone density testing for women aged 65 and older and for younger patients with risk factors, the screening-eligible population continues to expand across both developed and emerging markets, sustaining demand for central and peripheral densitometry systems.

Growing Burden of Fragility Fractures

The escalating burden of fragility fractures is a distinctive and powerful driver because it converts asymptomatic bone loss into visible clinical and economic consequences that health systems act to prevent. The International Osteoporosis Foundation reports up to 37 million fragility fractures each year in individuals over the age of 55, equivalent to 70 fractures every minute, and the World Health Organization has documented 178 million new fractures globally in 2019, with 455 million prevalent cases. Fragility fractures carry profound consequences, with loss of independence common after hip fracture and a substantial share of survivors requiring assistance or institutional care in the year that follows. These outcomes have made secondary fracture prevention and early detection a policy priority, embodied in fracture liaison services and screening programs that route at-risk patients to densitometry. Because a prior fracture sharply raises the risk of a subsequent one, each fragility fracture generates downstream demand not only for the diagnostic scan that identifies underlying bone weakness but for repeat monitoring during pharmacological treatment, and the enormous and rising health economic cost of fractures reinforces the case for the densitometry that anchors prevention.

Market Restraints

The bone densitometers market faces significant restraints and challenges, primarily related to reimbursement, awareness, and access. Reimbursement for bone density testing has historically been constrained in several health systems, and inadequate or declining payment can discourage providers from investing in equipment and can limit the frequency of monitoring scans, which slows both the installation of new systems and the replacement of ageing ones. A persistent lack of awareness among patients and, in some settings, among primary care providers means that the majority of people with osteoporosis remain undiagnosed until a fracture occurs, so a large share of the eligible population is never scanned despite the availability of technology. The high cost of central dual-energy X-ray absorptiometry systems, the requirement for a shielded room and trained technologists, and the need for periodic quality-control phantom calibration further limit access, particularly in developing countries and rural settings where a substantial share of the population lacks access to a densitometer at all. Evolving regulation adds to the burden, as the European Union Medical Device Regulation has imposed extensive clinical evidence and documentation requirements that raise the compliance cost of maintaining product availability and favor manufacturers with regulatory scale, a dynamic reflected in the multi-product recertification efforts of established suppliers. Competitive intensity is high in the peripheral and ultrasound segments, where numerous regional manufacturers supply lower-cost systems, compressing pricing, while cross-calibration differences between systems from different manufacturers complicate longitudinal monitoring when patients change devices. Trade policy and supply chain pressures on electronics, detectors, and X-ray components add a further constraint on manufacturing cost and lead times.

Bone Densitometers Market Segment Analysis

The global bone densitometers market is segmented by technology (axial (central) bone densitometry, peripheral bone densitometry, and radiofrequency echographic multi spectrometry), by application (osteoporosis and osteopenia diagnosis, fracture risk assessment, body composition analysis, and others), by portability (stationary and standalone systems and portable and tabletop systems), by end-user (hospitals, diagnostic imaging centers, ambulatory and specialty clinics, and others), and by geography (North America, Europe, Asia-Pacific, and the Rest of the World).

By Technology

Dominant Subsegment: Axial (Central) Bone Densitometry.

The axial (central) bone densitometry category is expected to dominate the market.

Dominant: Axial (Central) Bone Densitometry ~ 71%

The axial (central) bone densitometry segment accounted for a 71% share of the bone densitometers market in 2025. Axial systems dominate the technology structure because central dual-energy X-ray absorptiometry is the reference standard for diagnosing osteoporosis and the modality on which clinical guidelines, treatment thresholds, and monitoring protocols are built, and because the highest-value systems in the market are central platforms. Within this segment, central dual-energy X-ray absorptiometry is the overwhelming majority modality, measuring bone mineral density at the lumbar spine and proximal femur with high precision and low radiation dose, and it is the technology that generates T-scores against the World Health Organization diagnostic threshold. Manufacturers have concentrated their premium engineering here, with GE HealthCare Lunar iDXA and Prodigy systems and Hologic Horizon systems integrating the Trabecular Bone Score, vertebral fracture assessment, abdominal aortic calcification screening, and whole-body composition on a single platform. Central quantitative computed tomography forms a smaller part of the axial segment, providing volumetric density using standard computed tomography scanners with dedicated software. Peripheral bone densitometry, encompassing peripheral dual-energy X-ray absorptiometry, peripheral quantitative computed tomography, and quantitative ultrasound of the forearm and calcaneus, serves screening and point-of-care settings at lower cost, and radiofrequency echographic multispectrometry forms the fastest-growing technology as a radiation-free axial alternative. Axial central densitometry is expected to retain its dominant position throughout the forecast period, although radiation-free modalities are projected to capture a rising share of scan volume.

By Application

Dominant Subsegment: Osteoporosis and Osteopenia Diagnosis.

The osteoporosis and osteopenia diagnosis category is expected to dominate the market.

Dominant: Osteoporosis and Osteopenia Diagnosis ~ 74%

The osteoporosis and osteopenia diagnosis segment accounted for a 74% share of the bone densitometers market in 2025. Diagnosis of low bone mass dominates the application structure because it is the clinical purpose for which densitometry was created and remains the overwhelming majority of scan activity worldwide. The segment encompasses initial diagnostic testing against the World Health Organization T-score threshold, case-finding in postmenopausal women and older men, and evaluation of secondary osteoporosis arising from glucocorticoid use, endocrine disease, and other conditions, and its scale follows directly from the epidemiology of a disease that affects a large share of the population over 50. Fracture risk assessment forms the second application and a fast-growing one, as densitometry increasingly incorporates the Trabecular Bone Score and fracture-risk algorithms that combine bone mineral density with clinical risk factors to estimate the probability of future fracture, extending the clinical value of each scan beyond a single diagnostic threshold. Body composition analysis represents a distinct and expanding application, with central dual-energy X-ray absorptiometry systems used to quantify fat mass, lean mass, and visceral fat for metabolic health, weight management, sarcopenia assessment, and sports performance, a use case that manufacturers actively market as a separate revenue stream. Others encompass pediatric bone assessment and treatment monitoring. Osteoporosis and osteopenia diagnosis is expected to retain its dominant position throughout the forecast period, although body composition and fracture-risk applications are projected to grow faster.

Bone Densitometers Market Region Analysis

Dominant Region: North America

Dominant: North America ~ 44% (Largest)

North America accounted for a 44% share of the global bone densitometers market in 2025. The region leads the global market, driven by the high prevalence of osteoporosis, advanced healthcare infrastructure, strong adoption of bone density screening, and the presence of the two leading central dual-energy X-ray absorptiometry manufacturers, GE HealthCare and Hologic. The United States Centers for Disease Control and Prevention has reported a substantial age-adjusted prevalence of osteoporosis at the lumbar spine or femoral neck among adults aged 50 and over, with prevalence markedly higher in women than in men, sustaining a large screening and monitoring population. Adoption is supported by established reimbursement for bone densitometry, clinical guidelines recommending screening for women aged 65 and older, and a dense installed base of central systems in hospitals and imaging centers. The region is also the reference market for regulatory clearance and reimbursement innovation, having established a Current Procedural Terminology code for radiofrequency echographic multispectrometry effective from January 2024 and hosting early clinical and research adoption of radiation-free assessment, including its use by NASA. Continuous product innovation in bone quality metrics, body composition, and artificial intelligence, together with the extension of testing into primary care and wellness settings, positions North America as the dominant hub for bone densitometry.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is projected to register the fastest compound annual growth rate in the bone densitometers market through 2034. The region is emerging as a major growth driver due to its very large and rapidly ageing population, the rising prevalence of osteoporosis and fragility fractures, and expanding healthcare investment and infrastructure. By 2050, more than half of the world's osteoporotic fractures are expected to occur in Asia, and China alone is projected to see hip fracture incidence rise substantially over the coming decades, creating enormous latent demand for bone density screening and monitoring. Growing awareness, expanding insurance coverage, and government initiatives for the early diagnosis and management of osteoporosis are accelerating adoption, while a mature base of cost-effective regional manufacturers, particularly in South Korea, China, and Japan, is expanding access to affordable central and peripheral systems. South Korean manufacturers including OsteoSys supply competitively priced dual-energy X-ray absorptiometry and quantitative ultrasound systems across the region and beyond, Japanese manufacturers contribute quantitative ultrasound technology, and Chinese manufacturers supply high volumes to domestic and emerging markets. Regional growth is expected to exceed the global average across every technology segment, driven by the extension of testing from tertiary hospitals into primary care to reach an ageing population at scale.

Regional Commentary

North America

North America leads on value, installed base, and reimbursement precedence, holding a 44% share in 2025. The United States hosts the two leading central dual-energy X-ray absorptiometry manufacturers and established a Current Procedural Terminology code for radiofrequency echographic multispectrometry effective from January 2024. The Centers for Disease Control and Prevention has documented substantial osteoporosis prevalence among adults aged 50 and over, particularly in women. Adoption is supported by established reimbursement, guideline-based screening for women aged 65 and older, and a dense hospital and imaging-center installed base. Near-term dynamics are shaped by bone quality metrics, body composition applications, radiation-free assessment, and the extension of testing into primary care and wellness.

Europe

Europe is a mature and substantial market driven by a large ageing population, a high fragility fracture burden, and a strong emphasis on secondary fracture prevention through fracture liaison services. The health economic cost of fragility fractures in Europe is enormous and rising, reinforcing the policy case for screening and the densitometry that anchors it. The European Union Medical Device Regulation has imposed extensive evidentiary and documentation requirements that have reshaped product availability and favored manufacturers with regulatory scale, reflected in multi-product recertification efforts. Radiofrequency echographic multi spectrometry originated in Italy and has achieved notable European clinical adoption, while national screening programs and guideline recommendations gate utilization.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by a very large and rapidly ageing population, rising osteoporosis and fracture prevalence, and expanding healthcare investment. By 2050, more than half of global osteoporotic fractures are expected to occur in Asia, with China facing a sharp projected rise in hip fractures. Government initiatives, expanding insurance coverage, and a mature base of cost-effective manufacturers in South Korea, China, and Japan are accelerating adoption, and the region is extending testing from tertiary hospitals into primary care. South Korean and Chinese manufacturers supply affordable central and peripheral systems domestically and for export, while Japanese manufacturers contribute quantitative ultrasound technology.

Rest of World

The Rest of the World comprises the Middle East, Africa, and South America, where access is highly stratified. The Gulf Cooperation Council states and the larger South American markets, particularly Brazil, have invested in imaging capacity and increasingly perform contemporary bone densitometry, representing growing markets, while much of Africa lacks the densitometry infrastructure, trained workforce, and financing required, so a substantial share of osteoporosis is never diagnosed. High system and procedure costs limit access in developing countries and are often not covered by reimbursement. Regional growth will be driven by investment in diagnostic capacity, government health initiatives, awareness programs, and lower-cost portable and ultrasound-based systems from Asian and European manufacturers.

Bone Densitometers Market Competitive Landscape

The global bone densitometers market is classified as Moderately Fragmented. The competitive landscape is shaped by a small group of global leaders in central dual-energy X-ray absorptiometry alongside a large number of regional and specialist manufacturers in peripheral, ultrasound, and radiation-free modalities. GE HealthCare and Hologic hold leading positions in the high-value central segment, supported by decades of installed base, clinical evidence, and integrated bone quality and body composition applications, while numerous manufacturers across South Korea, China, Japan, Italy, France, and elsewhere compete in peripheral and ultrasound systems on price, portability, and access. Competition is intensifying in bone quality assessment, radiation-free axial modalities, and the extension of testing into primary care. The competitive landscape is evaluated across the following dimensions:

  • Market concentration: Moderately fragmented, with a small group of leaders holding the high-value central dual-energy X-ray absorptiometry segment and a long tail of regional and specialist manufacturers competing across peripheral, ultrasound, and radiation-free modalities.
  • Leading players: GE HealthCare Technologies Inc. and Hologic, Inc. lead in central dual-energy X-ray absorptiometry; Echolight S.p.A. leads in radiofrequency echographic multispectrometry; OsteoSys Co., Ltd. and BeamMed Ltd. lead in accessible peripheral and quantitative ultrasound systems.
  • Geographic reach: The leading central manufacturers operate global commercial and service organizations built on hospital and imaging-center relationships, while regional manufacturers in South Korea, China, Japan, and Europe leverage cost and portability advantages to penetrate primary care and emerging markets.
  • Product portfolio strength: Competitive advantage rests on combining bone mineral density with bone quality and body composition on a single platform, with portfolio breadth across central, peripheral, ultrasound, and radiation-free modalities determining position across care settings.
  • Pipeline and innovation focus: Development is concentrated in bone quality metrics such as the Trabecular Bone Score, artificial-intelligence-enabled reporting and fracture-risk prediction, radiation-free axial assessment, and portable point-of-care systems.
  • Regulatory standing: United States Food and Drug Administration clearance and European Union Medical Device Regulation certification have become decisive competitive credentials, with the evidentiary burden favoring manufacturers of scale, reflected in multi-product recertification efforts.
  • Strategic activity: Collaboration and validation are the defining dynamics, spanning reimbursement establishment, guideline inclusion, clinical validation studies, research and space-agency partnerships, and distribution agreements that extend reach into new geographies and care settings.

Bone Densitometers Market Recent Developmental Activities

In November 2025, Echolight S.p.A. demonstrated its radiation-free radiofrequency echographic multispectrometry bone density scanning at the Radiological Society of North America 2025 Congress in Chicago, presenting two new validation studies, including the application of the modality to assess bone changes during pregnancy and following total hip replacement. Strategic significance: presenting radiation-free axial assessment at the field's largest imaging congress, supported by fresh peer-reviewed validation in populations for whom radiation is a concern, advances the clinical adoption of a modality that extends bone assessment beyond the reach of fixed X-ray systems.

In February 2026, MRIguidance advanced BoneMRI, a radiation-free bone imaging solution, strengthening its commercial leadership to accelerate the deployment of quantitative magnetic-resonance-based bone density assessment. Strategic significance: the emergence of magnetic-resonance-based bone density represents a further radiation-free challenge to X-ray dual-energy absorptiometry, signaling that the technology frontier of the category is shifting toward modalities that avoid ionizing radiation while adding structural information.

Bone Densitometers Market Segmentation

Bone Densitometers Market Assessment by Technology

  • Axial (Central) Bone Densitometry

◦ Central Dual-Energy X-Ray Absorptiometry (DXA)

◦ Quantitative Computed Tomography (QCT)

  • Peripheral Bone Densitometry

◦ Peripheral Dual-Energy X-Ray Absorptiometry (pDXA)

◦ Peripheral Quantitative Computed Tomography (pQCT)

◦ Quantitative Ultrasound (QUS)

  • Radiofrequency Echographic Multi Spectrometry (REMS)

Bone Densitometers Market Assessment by Application

  • Osteoporosis and Osteopenia Diagnosis
  • Fracture Risk Assessment
  • Body Composition Analysis
  • Others

Bone Densitometers Market Assessment by Portability

  • Stationary and Standalone Systems
  • Portable and Tabletop Systems

Bone Densitometers Market Assessment by End-User

  • Hospitals
  • Diagnostic Imaging Centers
  • Ambulatory and Specialty Clinics
  • Others

Bone Densitometers Market Assessment by Geography

  • North America

◦ United States Bone Densitometers Market Size in USD million (2023-2034)

◦ Canada Bone Densitometers Market Size in USD million (2023-2034)

◦ Mexico Bone Densitometers Market Size in USD million (2023-2034)

  • Europe

◦ France Bone Densitometers Market Size in USD million (2023-2034)

◦ Germany Bone Densitometers Market Size in USD million (2023-2034)

◦ United Kingdom Bone Densitometers Market Size in USD million (2023-2034)

◦ Italy Bone Densitometers Market Size in USD million (2023-2034)

◦ Spain Bone Densitometers Market Size in USD million (2023-2034)

◦ Russia Bone Densitometers Market Size in USD million (2023-2034)

◦ Rest of Europe Bone Densitometers Market Size in USD million (2023-2034)

  • Asia-Pacific

◦ China Bone Densitometers Market Size in USD million (2023-2034)

◦ Japan Bone Densitometers Market Size in USD million (2023-2034)

◦ India Bone Densitometers Market Size in USD million (2023-2034)

◦ Australia Bone Densitometers Market Size in USD million (2023-2034)

◦ South Korea Bone Densitometers Market Size in USD million (2023-2034)

◦ Rest of Asia-Pacific Bone Densitometers Market Size in USD million (2023-2034)

  • Rest of the World

◦ Middle East Bone Densitometers Market Size in USD million (2023-2034)

◦ Africa Bone Densitometers Market Size in USD million (2023-2034)

◦ South America Bone Densitometers Market Size in USD million (2023-2034)

Key Takeaways from the Bone Densitometers Market Report Study

  • Market size analysis for the current bone densitometers market size (2025), and market forecast for 9 years (2026 to 2034).
  • Top key product, technology, and reimbursement developments, partnerships, and validations that happened over the last 3 years.
  • Key companies dominating the global bone densitometers market.
  • Various opportunities available for competitors in the bone densitometers market space.
  • What are the top-performing segments in 2025? How will these segments perform in 2034?
  • Which are the top-performing regions and countries in the current bone densitometers market scenario?
  • Which are the regions and countries where companies should concentrate their opportunities for bone densitometers market growth in the future?

Target Audience Who Can Benefit From This Bone Densitometers Market Report Study

  • Bone densitometers product providers
  • Research organizations and consulting companies
  • Bone densitometers-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in bone densitometers
  • Various end-users who want to know more about the bone densitometers market and the latest technological developments in the bone densitometers market.

Frequently Asked Questions:

Q1. At what rate is the bone densitometers market expected to grow?

The global bone densitometers market is projected to grow at a compound annual growth rate of 5.15% during the forecast period from 2026 to 2034.

Q2. What is the current and projected size of the bone densitometers market?

The global bone densitometers market was valued at USD 790 million in 2025 and is projected to reach USD 1.24 billion by 2034.

Q3. Which region dominates the bone densitometers market?

North America dominated the bone densitometers market with a 44% share in 2025, driven by the high prevalence of osteoporosis, advanced healthcare infrastructure, established reimbursement and guideline-based screening, and the presence of the two leading central dual-energy X-ray absorptiometry manufacturers. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by a very large and rapidly ageing population, a rising fracture burden, and a mature base of cost-effective manufacturers.

Table of Contents

1. Introduction

  • 1.1. Scope of the Report
  • 1.2. Market Segmentation
  • 1.3. Market Overview at a Glance

2. Executive Summary of Bone Densitometers Market

  • 2.1. Key Highlights and Market Snapshot

3. Key Factors Impacting the Bone Densitometers Market

  • 3.1. Market Drivers
    • 3.1.1. Rising Prevalence of Osteoporosis and Osteopenia
    • 3.1.2. Growing Burden of Fragility Fractures
    • 3.1.3. Ageing of the Global Population
    • 3.1.4. Technological Advancement and Bone Quality Assessment
    • 3.1.5. Emergence of Radiation-Free Axial Modalities
  • 3.2. Market Restraints
    • 3.2.1. Reimbursement Constraints and Limited Awareness
    • 3.2.2. High Cost and Limited Access in Developing Countries
    • 3.2.3. Regulatory Burden and Competitive Pricing Pressure
  • 3.3. Market Opportunities
    • 3.3.1. Extension of Bone Assessment into Primary Care
    • 3.3.2. Integration of Artificial Intelligence and Bone Quality Metrics

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

  • 5.1. The United States
  • 5.2. Europe
  • 5.3. Japan
  • 5.4. China

6. Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Bone Densitometers Market Assessment

  • 7.1. By Technology
    • 7.1.1. Axial (Central) Bone Densitometry
      • 7.1.1.1. Central Dual-Energy X-Ray Absorptiometry (DXA)
      • 7.1.1.2. Quantitative Computed Tomography (QCT)
    • 7.1.2. Peripheral Bone Densitometry
      • 7.1.2.1. Peripheral Dual-Energy X-Ray Absorptiometry (pDXA)
      • 7.1.2.2. Peripheral Quantitative Computed Tomography (pQCT)
      • 7.1.2.3. Quantitative Ultrasound (QUS)
    • 7.1.3. Radiofrequency Echographic Multi Spectrometry (REMS)
  • 7.2. By Application
    • 7.2.1. Osteoporosis and Osteopenia Diagnosis
    • 7.2.2. Fracture Risk Assessment
    • 7.2.3. Body Composition Analysis
    • 7.2.4. Others
  • 7.3. By Portability
    • 7.3.1. Stationary and Standalone Systems
    • 7.3.2. Portable and Tabletop Systems
  • 7.4. By End-User
    • 7.4.1. Hospitals
    • 7.4.2. Diagnostic Imaging Centers
    • 7.4.3. Ambulatory and Specialty Clinics
    • 7.4.4. Others
  • 7.5. By Geography
    • 7.5.1. North America
      • 7.5.1.1. United States Bone Densitometers Market Size in USD million (2023-2034)
      • 7.5.1.2. Canada Bone Densitometers Market Size in USD million (2023-2034)
      • 7.5.1.3. Mexico Bone Densitometers Market Size in USD million (2023-2034)
    • 7.5.2. Europe
      • 7.5.2.1. France Bone Densitometers Market Size in USD million (2023-2034)
      • 7.5.2.2. Germany Bone Densitometers Market Size in USD million (2023-2034)
      • 7.5.2.3. United Kingdom Bone Densitometers Market Size in USD million (2023-2034)
      • 7.5.2.4. Italy Bone Densitometers Market Size in USD million (2023-2034)
      • 7.5.2.5. Spain Bone Densitometers Market Size in USD million (2023-2034)
      • 7.5.2.6. Russia Bone Densitometers Market Size in USD million (2023-2034)
      • 7.5.2.7. Rest of Europe Bone Densitometers Market Size in USD million (2023-2034)
    • 7.5.3. Asia-Pacific
      • 7.5.3.1. China Bone Densitometers Market Size in USD million (2023-2034)
      • 7.5.3.2. Japan Bone Densitometers Market Size in USD million (2023-2034)
      • 7.5.3.3. India Bone Densitometers Market Size in USD million (2023-2034)
      • 7.5.3.4. Australia Bone Densitometers Market Size in USD million (2023-2034)
      • 7.5.3.5. South Korea Bone Densitometers Market Size in USD million (2023-2034)
      • 7.5.3.6. Rest of Asia-Pacific Bone Densitometers Market Size in USD million (2023-2034)
    • 7.5.4. Rest of the World
      • 7.5.4.1. Middle East Bone Densitometers Market Size in USD million (2023-2034)
      • 7.5.4.2. Africa Bone Densitometers Market Size in USD million (2023-2034)
      • 7.5.4.3. South America Bone Densitometers Market Size in USD million (2023-2034)

8. Bone Densitometers Market Competitive Landscape

  • 8.1. Competitive Analysis
  • 8.2. Company Share Analysis (Premium Offering)

9. Bone Densitometers Market Startup Funding and Investment Trends

10. Company and Product Profiles

  • 10.1. GE HealthCare Technologies Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Company Snapshot
    • 10.1.3. Financial Overview
    • 10.1.4. Product Listing
    • 10.1.5. Strategic Initiatives / Entropy
  • 10.2. Hologic, Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Company Snapshot
    • 10.2.3. Financial Overview
    • 10.2.4. Product Listing
    • 10.2.5. Strategic Initiatives / Entropy
  • 10.3. Echolight S.p.A.
    • 10.3.1. Company Overview
    • 10.3.2. Company Snapshot
    • 10.3.3. Financial Overview
    • 10.3.4. Product Listing
    • 10.3.5. Strategic Initiatives / Entropy
  • 10.4. OsteoSys Co., Ltd.
    • 10.4.1. Company Overview
    • 10.4.2. Company Snapshot
    • 10.4.3. Financial Overview
    • 10.4.4. Product Listing
    • 10.4.5. Strategic Initiatives / Entropy
  • 10.5. BeamMed Ltd.
    • 10.5.1. Company Overview
    • 10.5.2. Company Snapshot
    • 10.5.3. Financial Overview
    • 10.5.4. Product Listing
    • 10.5.5. Strategic Initiatives / Entropy
  • 10.6. Diagnostic Medical Systems (DMS) Group
    • 10.6.1. Company Overview
    • 10.6.2. Company Snapshot
    • 10.6.3. Financial Overview
    • 10.6.4. Product Listing
    • 10.6.5. Strategic Initiatives / Entropy
  • 10.7. Swissray International, Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Company Snapshot
    • 10.7.3. Financial Overview
    • 10.7.4. Product Listing
    • 10.7.5. Strategic Initiatives / Entropy
  • 10.8. Trivitron Healthcare Pvt. Ltd.
    • 10.8.1. Company Overview
    • 10.8.2. Company Snapshot
    • 10.8.3. Financial Overview
    • 10.8.4. Product Listing
    • 10.8.5. Strategic Initiatives / Entropy
  • 10.9. Furuno Electric Co., Ltd.
    • 10.9.1. Company Overview
    • 10.9.2. Company Snapshot
    • 10.9.3. Financial Overview
    • 10.9.4. Product Listing
    • 10.9.5. Strategic Initiatives / Entropy
  • 10.10. Xingaoyi Medical Equipment Co., Ltd.
    • 10.10.1. Company Overview
    • 10.10.2. Company Snapshot
    • 10.10.3. Financial Overview
    • 10.10.4. Product Listing
    • 10.10.5. Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us

List of Tables

  • Table 1: Global Bone Densitometers Market Size in USD million (2023-2034)
  • Table 2: Global Bone Densitometers Market Size by Technology in USD million (2023-2034)
  • Table 3: Global Bone Densitometers Market Size by Application in USD million (2023-2034)
  • Table 4: Global Bone Densitometers Market Size by Portability in USD million (2023-2034)
  • Table 5: Global Bone Densitometers Market Size by End-User in USD million (2023-2034)
  • Table 6: Bone Densitometers Market Size in North America in USD million (2023-2034)
  • Table 7: Bone Densitometers Market Size in United States in USD million (2023-2034)
  • Table 8: Bone Densitometers Market Size in Canada in USD million (2023-2034)
  • Table 9: Bone Densitometers Market Size in Mexico in USD million (2023-2034)
  • Table 10: Bone Densitometers Market Size in Europe in USD million (2023-2034)
  • Table 11: Bone Densitometers Market Size in France in USD million (2023-2034)
  • Table 12: Bone Densitometers Market Size in Germany in USD million (2023-2034)
  • Table 13: Bone Densitometers Market Size in United Kingdom in USD million (2023-2034)
  • Table 14: Bone Densitometers Market Size in Italy in USD million (2023-2034)
  • Table 15: Bone Densitometers Market Size in Spain in USD million (2023-2034)
  • Table 16: Bone Densitometers Market Size in Russia in USD million (2023-2034)
  • Table 17: Bone Densitometers Market Size in Rest of Europe in USD million (2023-2034)
  • Table 18: Bone Densitometers Market Size in Asia-Pacific in USD million (2023-2034)
  • Table 19: Bone Densitometers Market Size in China in USD million (2023-2034)
  • Table 20: Bone Densitometers Market Size in Japan in USD million (2023-2034)
  • Table 21: Bone Densitometers Market Size in India in USD million (2023-2034)
  • Table 22: Bone Densitometers Market Size in Australia in USD million (2023-2034)
  • Table 23: Bone Densitometers Market Size in South Korea in USD million (2023-2034)
  • Table 24: Bone Densitometers Market Size in Rest of Asia-Pacific in USD million (2023-2034)
  • Table 25: Bone Densitometers Market Size in Rest of the World in USD million (2023-2034)
  • Table 26: Bone Densitometers Market Size in Middle East in USD million (2023-2034)
  • Table 27: Bone Densitometers Market Size in Africa in USD million (2023-2034)
  • Table 28: Bone Densitometers Market Size in South America in USD million (2023-2034)
  • Table 29: Bone Densitometers Market Competitive Landscape
  • Table 30: Bone Densitometers Market Startup Funding and Investment Trends

List of Figures

  • Figure 1: Bone Densitometers Market Drivers
  • Figure 2: Bone Densitometers Market Restraints
  • Figure 3: Bone Densitometers Market Opportunities
  • Figure 4: Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
  • Figure 5: Regulatory Analysis of the Bone Densitometers Market (the United States)
  • Figure 6: Regulatory Analysis of the Bone Densitometers Market (Europe)
  • Figure 7: Regulatory Analysis of the Bone Densitometers Market (Japan)
  • Figure 8: Regulatory Analysis of the Bone Densitometers Market (China)
  • Figure 9: Porter's Five Forces Analysis of the Bone Densitometers Market
  • Figure 10: Competitive Analysis of the Bone Densitometers Market
  • Figure 11: Global Bone Densitometers Market Size in USD million (2023-2034)
  • Figure 12: Global Bone Densitometers Market Size by Technology in USD million (2023-2034)
  • Figure 13: Global Bone Densitometers Market Size by Application in USD million (2023-2034)
  • Figure 14: Global Bone Densitometers Market Size by Portability in USD million (2023-2034)
  • Figure 15: Global Bone Densitometers Market Size by End-User in USD million (2023-2034)
  • Figure 16: Bone Densitometers Market Size in North America in USD million (2023-2034)
  • Figure 17: Bone Densitometers Market Size in United States in USD million (2023-2034)
  • Figure 18: Bone Densitometers Market Size in Canada in USD million (2023-2034)
  • Figure 19: Bone Densitometers Market Size in Mexico in USD million (2023-2034)
  • Figure 20: Bone Densitometers Market Size in Europe in USD million (2023-2034)
  • Figure 21: Bone Densitometers Market Size in France in USD million (2023-2034)
  • Figure 22: Bone Densitometers Market Size in Germany in USD million (2023-2034)
  • Figure 23: Bone Densitometers Market Size in United Kingdom in USD million (2023-2034)
  • Figure 24: Bone Densitometers Market Size in Italy in USD million (2023-2034)
  • Figure 25: Bone Densitometers Market Size in Spain in USD million (2023-2034)
  • Figure 26: Bone Densitometers Market Size in Russia in USD million (2023-2034)
  • Figure 27: Bone Densitometers Market Size in Rest of Europe in USD million (2023-2034)
  • Figure 28: Bone Densitometers Market Size in Asia-Pacific in USD million (2023-2034)
  • Figure 29: Bone Densitometers Market Size in China in USD million (2023-2034)
  • Figure 30: Bone Densitometers Market Size in Japan in USD million (2023-2034)
  • Figure 31: Bone Densitometers Market Size in India in USD million (2023-2034)
  • Figure 32: Bone Densitometers Market Size in Australia in USD million (2023-2034)
  • Figure 33: Bone Densitometers Market Size in South Korea in USD million (2023-2034)
  • Figure 34: Bone Densitometers Market Size in Rest of Asia-Pacific in USD million (2023-2034)
  • Figure 35: Bone Densitometers Market Size in Rest of the World in USD million (2023-2034)
  • Figure 36: Bone Densitometers Market Size in Middle East in USD million (2023-2034)
  • Figure 37: Bone Densitometers Market Size in Africa in USD million (2023-2034)
  • Figure 38: Bone Densitometers Market Size in South America in USD million (2023-2034)
  • Figure 39: Bone Densitometers Market Competitive Landscape
  • Figure 40: Bone Densitometers Market Startup Funding and Investment Trends